Unlicensed pharmacies purporting to sell pharmaceutical drugs are thriving despite the efforts by the U.S. Drug Enforcement Administration to stop them.

Boston’s bid to hold two pharmacy benefit managers legally accountable for their alleged roles in the opioid epidemic under RICO and public nuisance claims was dismissed by a federal judge because it ...

Cole Schmidtknecht, 22, passed away on Jan. 21, 2024, after a sudden $500 spike in his asthma medication. A year to the day of his death, Cole’s parents, Shanon and William Schmidtknecht filed a ...

The charges in this lawsuit accuse Optum Rx - the PBM who determined Cole Schmidtknecht’s health plan - of negligence and punitive damages that led to the death of their son. The family’s ...

Healthcare providers are set to have another year where maximizing efficiency, above all, is paramount. Although both for-profit and nonprofit providers reported improved operating margins last ...

Things have gone from bad to worse for Tottenham Hotspur. Spurs have only won a single match since their demolition of Manchester City back in November, and fans must be wondering what sort of ...

Hoping to slay a second South Coast team at Old Trafford in the space of a week, Manchester United host Brighton & Hove Albion in Sunday afternoon’s Premier League scrap. The Red Devils needed a ...

In response to the findings of FTC, UnitedHealth’s OptumRx defended its practices while claiming it has helped patients save money on medications, noted Fortune. Meanwhile, at the same time, CVS ...

The Federal Trade Commission (FTC) released a report finding that OptumRX, Express Scripts, and CVS Caremark Rx are engaged in widespread price gouging, according to Fortune. The investigation ...

UnitedHealth Group's Optum Rx unit made a commitment to pass through ... sparking a wave of online vitriol targeting the health insurance industry. In the earnings report, the UnitedHealthcare ...

The Federal Trade Commission accused UnitedHealth's OptumRx, CVS Caremark, and Cigna's Express Scripts of pocketing over $7 billion in markups on generic specialty drugs over a 5-year period.